Novo Nordisk argues Medicare should negotiate the price for six of its insulin products separately, though they contain the ...

Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

A spokesperson confirmed the Danish drugmaker has asked U.S. regulators to clear an oral version of its weight loss drug ...

Novo Nordisk (NYSE:NVO) stock has experienced a significant decline, dropping 35% from over $90 in early March to around $58 ...

Eli Lilly and Novo Nordisk dominate the billion-dollar weight loss drug market. Lilly has announced positive trial results ...

A unique Novo Nordisk legal challenge to the Medicare drug pricing program could have big implications for the pharma ...

Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.

The agency and Novo Nordisk, which makes Ozempic, said Monday that they had learned about "several hundred units" of the drug ...

SAO PAULO (Reuters) - Novo Nordisk, the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil to boost production, it said on Monday. The ...

Bangkok, April 2025 – Chulalongkorn University, in collaboration with Novo Nordisk Pharma (Thailand ... the economic impact is already estimated at 1.2% of GDP, a figure projected to rise ...

Also Read: Novo Nordisk To Pay Around $2 Billion For Obesity Drug From China-Based Biotech The trial also demonstrated superiority to placebo for all confirmatory secondary outcomes assessed ...